Focused Ultrasound Thalamotomy for Refractory Essential Tremor: A Japanese Multicenter Single-Arm Study.


Journal

Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914

Informations de publication

Date de publication:
15 03 2021
Historique:
received: 27 08 2019
accepted: 10 10 2020
pubmed: 21 1 2021
medline: 12 5 2021
entrez: 20 1 2021
Statut: ppublish

Résumé

Several feasibility studies and a randomized, controlled, multicenter trial have demonstrated the safety and efficacy of unilateral transcranial magnetic resonance-guided focused ultrasound (FUS) lesioning of the ventral intermediate thalamic nucleus in treating essential tremor. To evaluate the safety and efficacy of FUS thalamotomy in a Japanese patient cohort through a prospective, multicenter, single-arm confirmatory trial. A total of 35 patients with disabling refractory essential tremor underwent unilateral FUS thalamotomy and were followed up for 12 post-treatment months. Safety was measured as the incidence and severity of treatment-related adverse events. Efficacy was measured as the tremor severity and quality of life improvements using the Clinical Rating Scale for Tremor and Questionnaire for Essential Tremor. The mean skull density ratio (SDR) was 0.47. There was a significant decrease in the mean postural tremor score of the treated hand from baseline to 12 mo by 56.4% (95% CI: 46.7%-66.1%; P < .001), which was maintained at last follow-up. Quality of life improved by 46.3% (mean overall Questionnaire for Essential Tremor score of 17.4 [95% CI: 12.1-22.7]) and there were no severe adverse events. The most frequent adverse event was gait disturbance and all events resolved. Unilateral FUS thalamotomy allowed significant and sustained tremor relief and improved the quality of life with an outstanding safety profile. The observed safety and efficacy of FUS thalamotomy were comparable to those reported in a previous multicenter study with a low SDR, and inclusion of the low SDR group did not affect effectiveness.

Sections du résumé

BACKGROUND
Several feasibility studies and a randomized, controlled, multicenter trial have demonstrated the safety and efficacy of unilateral transcranial magnetic resonance-guided focused ultrasound (FUS) lesioning of the ventral intermediate thalamic nucleus in treating essential tremor.
OBJECTIVE
To evaluate the safety and efficacy of FUS thalamotomy in a Japanese patient cohort through a prospective, multicenter, single-arm confirmatory trial.
METHODS
A total of 35 patients with disabling refractory essential tremor underwent unilateral FUS thalamotomy and were followed up for 12 post-treatment months. Safety was measured as the incidence and severity of treatment-related adverse events. Efficacy was measured as the tremor severity and quality of life improvements using the Clinical Rating Scale for Tremor and Questionnaire for Essential Tremor.
RESULTS
The mean skull density ratio (SDR) was 0.47. There was a significant decrease in the mean postural tremor score of the treated hand from baseline to 12 mo by 56.4% (95% CI: 46.7%-66.1%; P < .001), which was maintained at last follow-up. Quality of life improved by 46.3% (mean overall Questionnaire for Essential Tremor score of 17.4 [95% CI: 12.1-22.7]) and there were no severe adverse events. The most frequent adverse event was gait disturbance and all events resolved.
CONCLUSION
Unilateral FUS thalamotomy allowed significant and sustained tremor relief and improved the quality of life with an outstanding safety profile. The observed safety and efficacy of FUS thalamotomy were comparable to those reported in a previous multicenter study with a low SDR, and inclusion of the low SDR group did not affect effectiveness.

Identifiants

pubmed: 33469648
pii: 6104449
doi: 10.1093/neuros/nyaa536
doi:

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

751-757

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Congress of Neurological Surgeons 2021.

Auteurs

Keiichi Abe (K)

Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.

Shiro Horisawa (S)

Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.

Toshio Yamaguchi (T)

Shinyurigaoka General Hospital, Kanagawa, Japan.

Hiroki Hori (H)

Shinyurigaoka General Hospital, Kanagawa, Japan.

Kazumichi Yamada (K)

Division of Speech-Language-Hearing Therapy, Department of Rehabilitation, Faculty of Health Science, Kumamoto Health Science University, Chuo-ku, Japan.

Kimito Kondo (K)

Department of Neurology, Hokuto Hospital, Obihiro, Japan.

Hironori Furukawa (H)

Department of Neurosurgery, Kumagaya Hospital, Kumagaya, Japan.

Hajime Kamada (H)

Department of Neurology, Hokuto Hospital, Obihiro, Japan.

Haruhiko Kishima (H)

Department of Neurosurgery, Osaka University Graduate School of Medicine, Osaka, Japan.

Satoru Oshino (S)

Department of Neurosurgery, Osaka University Graduate School of Medicine, Osaka, Japan.

Hideki Mochizuki (H)

Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan.

Manabu Kanemoto (M)

Department of Neurosurgery, Saitoyukoukai, Osaka, Japan.

Hidehiro Hirabayashi (H)

Department of Neurosurgery, National Hospital Organization Nara Medical Center, Nara, Japan.

Kenji Fukutome (K)

Department of Neurosurgery, Ohnishi Neurological Center, Hyogo, Japan.

Hideyuki Ohnishi (H)

Department of Neurosurgery, Ohnishi Neurological Center, Hyogo, Japan.

Keiji Igase (K)

Department of Neurosurgery, Washokai Sadamoto Hospital, Ehime, Japan.

Ichiro Matsubara (I)

Department of Neurosurgery, Washokai Sadamoto Hospital, Ehime, Japan.

Takanori Ohnishi (T)

Department of Neurosurgery, Washokai Sadamoto Hospital, Ehime, Japan.

Kazuhiko Sadamoto (K)

Department of Neurosurgery, Washokai Sadamoto Hospital, Ehime, Japan.

Takaomi Taira (T)

Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH